Sanofi ends cancer drug trials

频道:社会 日期: 浏览:2

免费足球推介网www.hgbbs.vip)是国内最权威的足球赛事报道、预测平台。免费提供赛事直播,免费足球贴士,免费足球推介,免费专家贴士,免费足球推荐,最专业的免费足球推介网。

The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.

PARIS: Sanofi is ending development of a key cancer medicine in a blow to the French drugmaker’s pipeline of experimental therapies.

The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.

The move leaves Sanofi even more dependent for growth on blockbuster Dupixent, an antibody treatment for ailments ranging from asthma to severe eczema.

The company’s slate of experimental medicines has faced other setbacks, including safety concerns regarding multiple sclerosis treatment tolebrutinib.

,

皇冠信用网www.hg108.vip)是一个开放皇冠信用网即时比分、皇冠信用网开户的平台。皇冠信用网平台(www.hg108.vip)提供最新皇冠信用网登录,皇冠信用网APP下载包含新皇冠体育代理、会员APP,提供皇冠信用网代理开户、皇冠信用网会员开户业务。

,

Sanofi has included both amcenestrant and tolebrutinib as among six products in its pipeline that it prioritised as “potentially transformative” treatments.

Some investors are questioning the company’s growth trajectory after both of those medicines encountered problems.

UBS analysts last week downgraded Sanofi, saying there are few major catalysts coming soon to drive more excitement to the stock. — Bloomberg


转载说明:本文转载自Sunbet。

0 留言

评论

◎欢迎参与讨论,请在这里发表您的看法、交流您的观点。
验证码